The senolytic and anti-aging therapeutics market size has grown rapidly in recent years. It will grow from $2.18 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 19.2%. The growth in the historic period can be attributed to increasing incidence of age-related degenerative conditions, limited effectiveness of traditional regenerative therapies, expanding global elderly population, rising funding for cellular senescence research, and growing number of early-stage biotechnology longevity startups.
The senolytic and anti-aging therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 19.5%. The forecast period growth can be attributed to advancements in therapies targeting senescent cell elimination, integration of artificial intelligence in drug discovery for anti-aging, expansion of personalized treatment approaches in geriatric care, increasing demand for preventive healthcare solutions, and growing clinical validation of senolytic therapies. Major trends include development of geroscience-driven drug discovery pipelines, emergence of senescence biomarker-based diagnostics, advancement of precision longevity treatments, adoption of preventive anti-aging healthcare models, and combination therapies involving senolytic and senomorphic approaches.
The increasing aging population is expected to propel the growth of the senolytic and anti-aging therapeutics market going forward. An aging population refers to a population in which the proportion of elderly people is higher than the proportion of younger people. An increasing aging population is primarily due to rising life expectancy, as people are living longer and more individuals are reaching older age groups. Senolytic and anti-aging therapeutics support aging populations by targeting cellular senescence, reducing age-related diseases, enhancing tissue regeneration, and promoting healthier longevity outcomes. For instance, in February 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, the number of people aged 60 years and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the increasing aging population is driving the growth of the senolytic and anti-aging therapeutics market.
Leading companies operating in the senolytic and anti-aging therapeutics market are focusing on the development of innovative platforms such as senolytic immunotherapy platforms to target and eliminate senescent cells, thereby addressing underlying biological mechanisms of aging, chronic inflammation, and age-related diseases. Senolytic immunotherapy is a treatment approach that combines immune system activation with senolytic strategies to selectively identify and remove senescent (aged and non-functioning) cells from the body, helping restore tissue function, improve cellular health, and potentially slow degenerative processes associated with aging compared to conventional symptom-focused therapies. For example, in November 2025, Immorta Bio Inc., a US-based biotechnology company, announced the publication of an international patent application for SenoVax, a first-in-class senolytic immunotherapy designed to train the immune system to recognize and clear senescent cells more effectively. The therapy is engineered to stimulate targeted immune responses against aging cells, aiming to reduce chronic inflammation, improve regenerative capacity, and support healthier tissue function across multiple age-related conditions. By combining immunotherapeutic mechanisms with senolytic targeting, SenoVax represents an advanced approach in longevity science focused on addressing the root causes of biological aging rather than only managing its symptoms.
In May 2025, Altos Labs Inc., a US-based biotechnology firm, completed the acquisition of Dorian Therapeutics for an undisclosed valuation. Through this acquisition, Altos Labs intends to enhance its research capabilities in cellular rejuvenation and longevity by incorporating Dorian Therapeutics’ senescence-targeting technologies along with its preclinical therapeutic programs aimed at age-related disorders. Dorian Therapeutics Inc. is a US-based biotechnology company focused on developing senolytic and anti-aging therapies, particularly a novel drug class referred to as senoblockers.
Major companies operating in the senolytic and anti-aging therapeutics market are AbbVie Inc., Alkahest Inc., Altos Labs Inc., BlueRock Therapeutics, Calico Life Sciences LLC, Cambrian BioPharma Inc., Celularity Inc., Eli Lilly and Company, Elevian, Elysium Health Inc., Eos SENOLYTIX Inc., Gero PTE. LTD., HexemBio Inc., Insilico Medicine Inc., Juvenescence Limited, Life Biosciences Inc., Merck & Co. Inc., Novartis AG, Oisín Biotechnologies Inc., Pfizer Inc., Retro Biosciences Inc., Rubedo Life Sciences Inc., Stealth BioTherapeutics, UNITY Biotechnology Inc.
North America was the dominant region in the senolytic and anti-aging therapeutics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in senolytic and anti-aging therapeutics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the senolytic and anti-aging therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The senolytic and anti-aging therapeutics market consists of sales of senolytic agents, senomorphic drugs, and anti-aging pharmaceuticals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or developers of the therapies, whether to other entities (including hospitals, research institutes, distributors, pharmacies, wellness centers, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The senolytic and anti-aging therapeutics market research report is one of a series of new reports that provides senolytic and anti-aging therapeutics market statistics, including senolytic and anti-aging therapeutics industry global market size, regional shares, competitors with a senolytic and anti-aging therapeutics market share, detailed senolytic and anti-aging therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the senolytic and anti-aging therapeutics industry. This senolytic and anti-aging therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The senolytic and anti-aging therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 19.5%. The forecast period growth can be attributed to advancements in therapies targeting senescent cell elimination, integration of artificial intelligence in drug discovery for anti-aging, expansion of personalized treatment approaches in geriatric care, increasing demand for preventive healthcare solutions, and growing clinical validation of senolytic therapies. Major trends include development of geroscience-driven drug discovery pipelines, emergence of senescence biomarker-based diagnostics, advancement of precision longevity treatments, adoption of preventive anti-aging healthcare models, and combination therapies involving senolytic and senomorphic approaches.
The increasing aging population is expected to propel the growth of the senolytic and anti-aging therapeutics market going forward. An aging population refers to a population in which the proportion of elderly people is higher than the proportion of younger people. An increasing aging population is primarily due to rising life expectancy, as people are living longer and more individuals are reaching older age groups. Senolytic and anti-aging therapeutics support aging populations by targeting cellular senescence, reducing age-related diseases, enhancing tissue regeneration, and promoting healthier longevity outcomes. For instance, in February 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, the number of people aged 60 years and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the increasing aging population is driving the growth of the senolytic and anti-aging therapeutics market.
Leading companies operating in the senolytic and anti-aging therapeutics market are focusing on the development of innovative platforms such as senolytic immunotherapy platforms to target and eliminate senescent cells, thereby addressing underlying biological mechanisms of aging, chronic inflammation, and age-related diseases. Senolytic immunotherapy is a treatment approach that combines immune system activation with senolytic strategies to selectively identify and remove senescent (aged and non-functioning) cells from the body, helping restore tissue function, improve cellular health, and potentially slow degenerative processes associated with aging compared to conventional symptom-focused therapies. For example, in November 2025, Immorta Bio Inc., a US-based biotechnology company, announced the publication of an international patent application for SenoVax, a first-in-class senolytic immunotherapy designed to train the immune system to recognize and clear senescent cells more effectively. The therapy is engineered to stimulate targeted immune responses against aging cells, aiming to reduce chronic inflammation, improve regenerative capacity, and support healthier tissue function across multiple age-related conditions. By combining immunotherapeutic mechanisms with senolytic targeting, SenoVax represents an advanced approach in longevity science focused on addressing the root causes of biological aging rather than only managing its symptoms.
In May 2025, Altos Labs Inc., a US-based biotechnology firm, completed the acquisition of Dorian Therapeutics for an undisclosed valuation. Through this acquisition, Altos Labs intends to enhance its research capabilities in cellular rejuvenation and longevity by incorporating Dorian Therapeutics’ senescence-targeting technologies along with its preclinical therapeutic programs aimed at age-related disorders. Dorian Therapeutics Inc. is a US-based biotechnology company focused on developing senolytic and anti-aging therapies, particularly a novel drug class referred to as senoblockers.
Major companies operating in the senolytic and anti-aging therapeutics market are AbbVie Inc., Alkahest Inc., Altos Labs Inc., BlueRock Therapeutics, Calico Life Sciences LLC, Cambrian BioPharma Inc., Celularity Inc., Eli Lilly and Company, Elevian, Elysium Health Inc., Eos SENOLYTIX Inc., Gero PTE. LTD., HexemBio Inc., Insilico Medicine Inc., Juvenescence Limited, Life Biosciences Inc., Merck & Co. Inc., Novartis AG, Oisín Biotechnologies Inc., Pfizer Inc., Retro Biosciences Inc., Rubedo Life Sciences Inc., Stealth BioTherapeutics, UNITY Biotechnology Inc.
North America was the dominant region in the senolytic and anti-aging therapeutics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in senolytic and anti-aging therapeutics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the senolytic and anti-aging therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The senolytic and anti-aging therapeutics market consists of sales of senolytic agents, senomorphic drugs, and anti-aging pharmaceuticals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or developers of the therapies, whether to other entities (including hospitals, research institutes, distributors, pharmacies, wellness centers, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The senolytic and anti-aging therapeutics market research report is one of a series of new reports that provides senolytic and anti-aging therapeutics market statistics, including senolytic and anti-aging therapeutics industry global market size, regional shares, competitors with a senolytic and anti-aging therapeutics market share, detailed senolytic and anti-aging therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the senolytic and anti-aging therapeutics industry. This senolytic and anti-aging therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Senolytic And Anti-Aging Therapeutics Market Characteristics
3. Senolytic And Anti-Aging Therapeutics Market Supply Chain Analysis
4. Global Senolytic And Anti-Aging Therapeutics Market Trends And Strategies
5. Senolytic And Anti-Aging Therapeutics Market Analysis Of End Use Industries
7. Global Senolytic And Anti-Aging Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Senolytic And Anti-Aging Therapeutics Total Addressable Market (TAM) Analysis for the Market
9. Senolytic And Anti-Aging Therapeutics Market Segmentation
10. Senolytic And Anti-Aging Therapeutics Market Regional And Country Analysis
11. Asia-Pacific Senolytic And Anti-Aging Therapeutics Market
12. China Senolytic And Anti-Aging Therapeutics Market
13. India Senolytic And Anti-Aging Therapeutics Market
14. Japan Senolytic And Anti-Aging Therapeutics Market
15. Australia Senolytic And Anti-Aging Therapeutics Market
16. Indonesia Senolytic And Anti-Aging Therapeutics Market
17. South Korea Senolytic And Anti-Aging Therapeutics Market
18. Taiwan Senolytic And Anti-Aging Therapeutics Market
19. South East Asia Senolytic And Anti-Aging Therapeutics Market
20. Western Europe Senolytic And Anti-Aging Therapeutics Market
21. UK Senolytic And Anti-Aging Therapeutics Market
22. Germany Senolytic And Anti-Aging Therapeutics Market
23. France Senolytic And Anti-Aging Therapeutics Market
24. Italy Senolytic And Anti-Aging Therapeutics Market
25. Spain Senolytic And Anti-Aging Therapeutics Market
26. Eastern Europe Senolytic And Anti-Aging Therapeutics Market
27. Russia Senolytic And Anti-Aging Therapeutics Market
28. North America Senolytic And Anti-Aging Therapeutics Market
29. USA Senolytic And Anti-Aging Therapeutics Market
30. Canada Senolytic And Anti-Aging Therapeutics Market
31. South America Senolytic And Anti-Aging Therapeutics Market
32. Brazil Senolytic And Anti-Aging Therapeutics Market
33. Middle East Senolytic And Anti-Aging Therapeutics Market
34. Africa Senolytic And Anti-Aging Therapeutics Market
36. Senolytic And Anti-Aging Therapeutics Market Competitive Landscape And Company Profiles
37. Senolytic And Anti-Aging Therapeutics Market Other Major And Innovative Companies
41. Senolytic And Anti-Aging Therapeutics Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Senolytic And Anti-Aging Therapeutics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses senolytic and anti-aging therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for senolytic and anti-aging therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The senolytic and anti-aging therapeutics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Class: Senolytics; Senomorphics; Nicotinamide Adenine Dinucleotide Precursors; Mechanistic Target Of Rapamycin Inhibitors2) By Therapy Type: Small Molecule Therapy; Biologic Therapy; Gene Therapy; Immunotherapy
3) By Route Of Administration: Oral; Injectable; Topical; Implantable
4) By Application: Cardiovascular Disease; Frailty And Musculoskeletal Aging; Neurodegeneration; Ophthalmology
5) By End User: Academic Medical Centers; Geriatric Clinics; Consumer Wellness; Clinical Research Organizations
Subsegments:
1) By Senolytics: Dasatinib And Quercetin Therapeutics; Fisetin Based Therapeutics; Flavonoid Derived Senolytic Agents; Cellular Senescence Targeting Compounds; B Cell Lymphoma Protein Inhibitors2) By Senomorphics: Anti Inflammatory Senomorphic Agents; Cytokine Modulating Therapeutics; Cellular Stress Response Modulators; Fibrosis Reducing Therapeutics; Oxidative Stress Reducing Compounds
3) By Nicotinamide Adenine Dinucleotide Precursors: Nicotinamide Riboside Therapeutics; Nicotinamide Mononucleotide Therapeutics; Tryptophan Derived Precursors; Niacin Based Therapeutics; Cellular Energy Enhancing Compounds
4) By Mechanistic Target Of Rapamycin Inhibitors: Rapamycin Based Therapeutics; Everolimus Based Therapeutics; Temsirolimus Based Therapeutics; Protein Kinase Inhibitor Therapeutics; Autophagy Regulating Compounds
Companies Mentioned: AbbVie Inc.; Alkahest Inc.; Altos Labs Inc.; BlueRock Therapeutics; Calico Life Sciences LLC; Cambrian BioPharma Inc.; Celularity Inc.; Eli Lilly and Company; Elevian; Elysium Health Inc.; Eos SENOLYTIX Inc.; Gero PTE. LTD.; HexemBio Inc.; Insilico Medicine Inc.; Juvenescence Limited; Life Biosciences Inc.; Merck & Co. Inc.; Novartis AG; Oisín Biotechnologies Inc.; Pfizer Inc.; Retro Biosciences Inc.; Rubedo Life Sciences Inc.; Stealth BioTherapeutics; UNITY Biotechnology Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- AbbVie Inc.
- Alkahest Inc.
- Altos Labs Inc.
- BlueRock Therapeutics
- Calico Life Sciences LLC
- Cambrian BioPharma Inc.
- Celularity Inc.
- Eli Lilly and Company
- Elevian
- Elysium Health Inc.
- Eos SENOLYTIX Inc.
- Gero PTE. LTD.
- HexemBio Inc.
- Insilico Medicine Inc.
- Juvenescence Limited
- Life Biosciences Inc.
- Merck & Co. Inc.
- Novartis AG
- Oisín Biotechnologies Inc.
- Pfizer Inc.
- Retro Biosciences Inc.
- Rubedo Life Sciences Inc.
- Stealth BioTherapeutics
- UNITY Biotechnology Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.6 Billion |
| Forecasted Market Value ( USD | $ 5.31 Billion |
| Compound Annual Growth Rate | 19.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
